Payment overview · 2025
General Payments
$447.91
20 reported records · 12 companies
Healthcare provider profile · identity verified
Nse Akpe, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · HARRISBURG, PA · NPI 1861590580
Verified facts
What the public records show
CMS Open Payments records show Nse Akpe, PAC received $447.91 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.75 | 22.7% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $61.07 | 13.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.96 | 10.7% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$45.51 | 10.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.45 | 8.8% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $32.22 | 7.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.75 | 5.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.49 | 4.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.98 | 4.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.02 | 4.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.21 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.50 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $447.91 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $101.75 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $61.07 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.96 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $45.51 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $44.64 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.45 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $32.22 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 49 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 582 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 115 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 371 | 93 |
| Gabapentin | Gabapentin | 340 | 83 |
| Lisinopril | Lisinopril | 303 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 57 |
| Metformin Hcl | Metformin Hcl | 276 | 62 |
| Montelukast Sodium | Montelukast Sodium | 238 | 44 |
| Losartan Potassium | Losartan Potassium | 196 | 35 |
| Omeprazole | Omeprazole | 195 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 191 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 36 |
| Famotidine | Famotidine | 189 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 37 |
| Furosemide | Furosemide | 160 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 38 |
| Ibuprofen | Ibuprofen | 125 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 118 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 23 |
| Trazodone Hcl | Trazodone Hcl | 104 | 22 |
| Jardiance | Empagliflozin | 99 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 22 |
| Carvedilol | Carvedilol | 91 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 29 |
| Lovastatin | Lovastatin | 88 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 85 | 15 |
| Sertraline Hcl | Sertraline Hcl | 80 | 19 |
| Potassium Chloride | Potassium Chloride | 78 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 77 | 18 |
| Glipizide | Glipizide | 75 | 13 |
| Atenolol | Atenolol | 72 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Celecoxib | Celecoxib | 65 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 14 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 61 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Nifedipine Er | Nifedipine | 52 | 13 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | 11 |
| Simvastatin | Simvastatin | 51 | 13 |
| Eliquis | Apixaban | 49 | 12 |
| Valacyclovir | Valacyclovir Hcl | 49 | suppressed |
| Allopurinol | Allopurinol | 47 | 12 |
| Prednisone | Prednisone | 46 | suppressed |
| Glipizide Er | Glipizide | 45 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 45 | 15 |
| Ozempic | Semaglutide | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | 11 |
| Tramadol Hcl | Tramadol Hcl | 31 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 18 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 14 |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $447.91 · 20 records | Novo Nordisk Inc | CAPVAXIVE, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, MINIMED 780G, MOUNJARO, QULIPTA, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error